Polynucleotides and polypeptides of the erythropoietin gene
The present invention relates to new polynucleotides deriving from the nucleotide sequence of the EPO gene and comprising new SNPs, new polypeptides derived from the natural EPO protein and comprising at least one mutation caused by the SNPs of the invention as well as their therapeutic uses.
1. An isolated polypeptide comprising amino acids 28 through 193 of the amino acid sequence SEQ ID NO. 2 and having SNP G104S.
2. A hyperglycosylated analog of an isolated polypeptide comprising amino acids 28 through 193 of the amino acid sequence SEQ ID NO. 2 and having SNP G104S.
3. An isolated polypeptide comprising an amino acid sequence having at least 95% identity with:
a) the amino acid sequence SEQ ID NO. 2; or
b) amino acids 28 through 193 of the amino acid sequence SEQ ID NO. 2; wherein said polypeptide comprises the coding SNP G104S.
4. An hyperglycosylated analog of an isolated polypeptide of claim 3 .
5. A therapeutic agent comprising a polypeptide of claim 3 .
6. A therapeutic agent comprising a hyperglycosylated analog of claim 4 .